Home
Live Updates
EMA Validates MAA for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer : comparemela.com
EMA Validates MAA for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
The MAA seeking the approval of tisotumab vedotin in select patients with recurrent or metastatic cervical cancer has been validated by the EMA.
Related Keywords
United States ,
Gonzalez Martin ,
Pfizer ,
European Medicines Agency ,
Fema ,
Marketing Authorization Application ,
Maa ,
Tisotumab Vedotin ,
Antibody Drug Conjugate ,
Sadc ,
Cervical Cancer ,
Gynecologic Cancer ,
Phase 3 Innovatv 301 Trial ,
Phase 2 Innovatv 204 ,
Genmab ,
comparemela.com © 2020. All Rights Reserved.